Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination antihypertensive therapy in pregnancy: labetalol + nifedipine versus methyldopa + nifedipine
PACTR202409510583842Phase 3Recruiting
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Hypertensive disorders of pregnancy (HDP), preeclampsia, pregnancy-induced hypertension (PIH) and 1 more comparing Labetalol + nifedipine with Methyldopa + nifedipine (2 arms). Primary endpoints: Achievement of target blood pressure and Drug dose required to achieve target blood pressure. Started Feb 2024; status: recruiting.
02
Drugs
labetalolnifedipinemethyldopa
03
Conditions
Hypertensive disorders of pregnancy (HDP)preeclampsiapregnancy-induced hypertension (PIH)chronic hypertension in pregnancy (CHTN)
Beyond the preview
Go deeper on PACTR202409510583842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202409510583842.